GenSight Biologics to Present at Upcoming 2022 Medical Conferences

GenSight Biologics to Present at Upcoming Industry and Investor Conferences

GenSight Biologics Announces Successful Completion of LUMEVOQ® Engineering Batch Validating Implemented Corrective Actions

GenSight Biologics strengthens its management team to support the launch of LUMEVOQ® in Europe

GenSight Biologics Reports Interim Financial Results for the First Half of 2022

GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®

GenSight Biologics Announces Participation and Presentation of GS010 Clinical Data at EUNOS 2022

GenSight Biologics Announces Publication of a Study of the impact of LHON disease on the lives of Patients and Relatives in Journal of Neuro-Ophthalmology

Annual General Meeting on May 25, 2022 Procedures for obtaining preparatory documents for the General Meeting

GenSight Biologics Announces the Filing of its 2021 Universal Registration Document